Stay updated on Pembrolizumab Combo With Local Ablation in HCC Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab Combo With Local Ablation in HCC Clinical Trial page.

Latest updates to the Pembrolizumab Combo With Local Ablation in HCC Clinical Trial page
- Check6 days agoNo Change Detected
- Check13 days agoChange DetectedAdded Revision: v3.4.2 and removed the previous Revision: v3.4.1 notice, along with removing the funding status operating notice.SummaryDifference0.4%

- Check20 days agoChange DetectedA site-wide funding notice was added and the page version updated from v3.4.0 to v3.4.1.SummaryDifference0.4%

- Check28 days agoChange DetectedA glossary is now displayed, and the QC update label has been capitalized from 'Last Update Submitted that met QC Criteria' to 'Last Update Submitted that Met QC Criteria'. The No FEAR Act Data label appears with updated capitalization, replacing the previous 'No FEAR Act data', and the revision reference updated from v3.3.4 to v3.4.0. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.2%

- Check42 days agoChange DetectedRevision updated from v3.3.3 to v3.3.4 with no changes to study details, eligibility criteria, or results. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check63 days agoChange DetectedLocations section added for Lower Saxony, listing Hanover, Germany as a study site. The HHS Vulnerability Disclosure link in the footer was removed.SummaryDifference0.2%

- Check92 days agoChange DetectedFooter shows Revision: v3.3.2 replacing v3.2.0. There are no changes to the study details, eligibility criteria, or results on the page.SummaryDifference0.1%

Stay in the know with updates to Pembrolizumab Combo With Local Ablation in HCC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab Combo With Local Ablation in HCC Clinical Trial page.